Axsome Therapeutics, Inc.'s stock has surged over 30% since my last “Hold” rating, driven by key catalysts like the litigation settlement with Teva Pharmaceuticals, announced today.
Hosted on MSN1mon
Axsome settles patent litigation with Teva over AUVELITYNEW YORK - Axsome Therapeutics, Inc. (NASDAQ:AXSM), a $5.1 billion market cap biopharmaceutical company with impressive 91% gross profit margins, has reached a settlement agreement with Teva ...
Hosted on MSN29d
Axsome stock target raised to $190 on Teva litigation resolutionThe revision follows Axsome's announcement that it has successfully resolved its patent litigation with Teva Pharmaceuticals regarding Auvelity, ensuring that a generic version of the drug will ...
Axsome grants Teva a license to sell generic Auvelity starting in 2038 or 2039, resolving all ongoing patent litigation. Axsome's Q4 and full-year 2024 Auvelity sales are expected at $92.6M and $ ...
Under the terms of the settlement agreement, Axsome will grant Teva a license to sell its generic version of AUVELITY beginning on or after March 31, 2039, if pediatric exclusivity is granted for ...
Shares of Axsome Therapeutics AXSM jumped 20.2% on Monday after the company announced that it has entered into a settlement agreement with Teva Pharmaceuticals TEVA related to patents for the ...
Axsome Therapeutics (NASDAQ:AXSM) stock rallied 15% in morning trading on news it has settled patent litigation with Teva (NYSE:TEVA) over its antidepressant drug Auvelity. Axsome (NASDAQ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback